comparemela.com

Latest Breaking News On - Matthew pillar - Page 3 : comparemela.com

What's True Of Mice ≠ What's True Of Men

As ATMPs advance, scientists are calling out the limited value of mouse models in pharmacological re-search and testing. LIfT Biosciences’.

Cambridge
Cambridgeshire
United-kingdom
Alex-blyth
Matthew-pillar
Bioprocess-online

Navigating A Clinical Hold

FDA-ordered clinical holds are on the rise, and biologics IND are driving them. Immunome CEO Purnanand Sarma, Ph.D. shares his take on the role of.

Purnanand-sarma
Michael-yee
Matthew-pillar
Bioprocess-online
Clinical-biopharma
Immunome-president

The Coming Wave Of Radio(bio)pharmaceuticals

Convergent Therapeutics is bullish on the combination of radioisotopes and antibodies to direct radiation directly to cancer cells. As enabling.

Philip-kantoff
Pluvicto-lu
Alex-brown
Department-of-energy
Novartis
Development-burgeon
Cardinal-health
Serono
Harvard-medical-school-professor
Memorial-sloan-kettering-cancer-center
Convergent-therapeuticsa-brown-university-medical
Dana-farber-cancer-institute

Formulation Alternatives Looking Beyond Parenteral Biologics

2022 could be a breakout year for oral, intranasal, and inhalable biologics. As innovative biopharma companies clear formulation, stability, and.

Georgia
United-states
Pennsylvania
Grand-view
Venezuela
Americans
Venezuelan
Augmenta-bioworks
Kartik-chandran
Sean-tuckerin
A-celltrion-intract
Ted-ross

Competitive Differentiation In A Crowded Market

When is it time for an emerging biopharma company to truly emerge, and what goes into its competitive positioning? Biopharma industry veteran Allan.

Allan-shaw
Elizabeth-holmes-theranos
Matthew-pillar
Bioprocess-online
Biopharma-special-advisor
Board-memberclearly

vimarsana © 2020. All Rights Reserved.